News + Resources

Keep up with the latest

Featured

This Scientist Is Building Custom Gene-Editing Tools

This Scientist Is Building Custom Gene-Editing Tools

Scribe Therapeutics Reports Preclinical Data Validating its CRISPR Genome Editing and Epigenome Modifying Technologies for Addressing Cardiometabolic Disease at American Heart Association (AHA) Scientific Sessions 2024

November 25, 2024

Scribe Therapeutics Reports Preclinical Data Validating its CRISPR Genome Editing and Epigenome Modifying Technologies for Addressing Cardiometabolic Disease at American Heart Association (AHA) Scientific Sessions 2024

November 25, 2024

CRISPR 2.0, the Next Generation

June 21, 2024

Aspen Ideas: Health

CRISPR 2.0, the Next Generation

June 21, 2024

The Age of CRISPR: Engineering the Future of Genetic Medicine

February 23, 2024

TEDxBerkeley

The Age of CRISPR: Engineering the Future of Genetic Medicine

February 23, 2024

Scribe Therapeutics Picks Cholesterol-Lowering As First In Vivo Gene Target

February 7, 2024

Scrip

Scribe Therapeutics Picks Cholesterol-Lowering As First In Vivo Gene Target

February 7, 2024

All Stories

Exciting new CRISPR-CasX variant could be ‘Swiss army knife’ for genetics

February 5, 2019

Silicon Republic

Exciting new CRISPR-CasX variant could be ‘Swiss army knife’ for genetics

February 5, 2019

Silicon Republic

Scribe, Vertex add to gene therapy's advance with $1B+ deal, near-term BLA

September 27, 2022

BioWorld

Sanofi ThiNKs Scribe’s CRISPR Approach Can Advance Its NK Cell Therapy Goals

September 27, 2022

Scrip

Sanofi’s NK cell toolbox grows with Scribe’s next-gen editor

September 27, 2022

BioCentury

Natural killers gain more attention with major Franco-US collab

September 27, 2022

The Pharma Letter

Sanofi partners with Scribe to gain gene editing tools for cell therapy work

September 27, 2022

Biopharma Dive

Sanofi turns to a Jennifer Doudna gene editing upstart for next-gen NK cell alliance

September 27, 2022

Endpoints News

Scribe Therapeutics to Participate in Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Days

March 31, 2023

Scribe Therapeutics to Participate in Four Upcoming Conferences

November 17, 2022

Scribe Therapeutics to Participate in Upcoming Investor Conferences

September 29, 2022

Scribe Therapeutics Announces Research Collaboration with Sanofi to Accelerate Breakthrough CRISPR-based Cell Therapies for Cancer

September 27, 2022

Scribe Therapeutics Announces Expansion of San Francisco Bay Area Headquarters, 3 Key Senior Hires

July 26, 2022

Scribe Therapeutics to Participate in SVB Securities Biopharma Private Company Connect

July 15, 2022

Publications and presentations

Scribe Corporate Deck 2025 Q1

February 3, 2025

CasX enzymes comprise a distinct family of RNA-guided genome editors

February 4, 2019

Nature

Efficient genome editing in the mouse brain by local delivery of engineered Cas9 ribonucleoprotein complexes

May 1, 2017

Nature Biotechnology

Targeted gene knock-in by homology-directed genome editing using Cas9 ribonucleoprotein and AAV donor delivery

March 2, 2017

Nucleic Acids Research

Profiling of engineering hotspots identifies an allosteric CRISPR-Cas9 switch

June 1, 2016

Nature Biotechnology

Multi-reporter selection for the design of active and more specific zinc-finger nucleases for genome editing

January 7, 2016

Nature Communications

Enhanced homology-directed human genome engineering by controlled timing of CRISPR/Cas9 delivery

December 15, 2014

eLife

Programmable RNA recognition and cleavage by CRISPR/Cas9

December 11, 2014

Nature

MicroRNA-mediated switching of chromatin-remodelling complexes in neural development

July 30, 2009

Nature